Wells Fargo new coverage Autolus Therapeutics Overweight
A Wells Fargo analyst initiated new coverage Autolus Therapeutics (NASDAQ: AUTL) Overweight rating and a price target of $8.00. Prior to this rating, Autolus Therapeutics had 9 buy...
Neutral
or
Autolus Therapeutics News & Analysis
-
-
Autolus Therapeutics announces resignation of Chief Financial Officer
Autolus Therapeutics plc (Nasdaq: NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Lucinda...
-
Autolus Therapeutics earnings beat by $0.10, revenue fell short of estimates
Investing.com - Autolus Therapeutics (NASDAQ: AUTL) reported first quarter EPS of $-0.170, $0.10 better than the analyst estimate of $-0.269. Revenue for the quarter came in at $4.5M versus...
-
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today...
-
Autolus Therapeutics Earnings, Revenue beat In Q3
Investing.com - Autolus Therapeutics reported on Thursday third quarter {{erl-1081659||earnings that beat analysts' forecasts and revenue that topped expectations. Autolus Therapeutics...
-
Autolus Therapeutics Misses Q2 EPS by 4c
Autolus Therapeutics (NASDAQ:AUTL) reported Q2 EPS of ($0.46), $0.04 worse than the analyst estimate of...
-
Blackstone to Invest $250M in Autolus Therapeutics
By Sam Boughedda Investing.com — U.K.-based biopharmaceutical firm Autolus Therapeutics Ltd (NASDAQ:AUTL) announced Monday that Blackstone (NYSE:BX) will invest as much as $250 million...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.99%
Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Technology, Basic Materials and Consumer Services sectors propelled shares lower. At the close in NYSE,...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
